Dry Powder Inhaler Formulation of Ensifentrine Improves Lung Function, Phase 2 Data Show
Treatment with a dry powder inhaler (DPI) formulation of ensifentrine led to clinically meaningful and sustained improvement in lung function in people with moderate to severe chronic obstructive pulmonary disease (COPD), according to early data from a Phase 2 trial. Ensifentrine (RPL554) is an inhibitor of the phosphodiesterase…